Table 1. Associations of RBM3 expression in primary tumors with clinicopathological parameters.
| All | Intestinal type | Pancreatobiliary type | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n | median (range) | P | n | median (range) | P | n | median (range) | P | |
| Age | |||||||||
| Q1 (38–61) | 39 | 1.81 (0.13–3.00) | 0.799 | 18 | 1.82 (0.27–2.85) | 0.539 | 21 | 1.81 (0.13–3.00) | 0.413 |
| Q2 (62–67) | 43 | 1.70 (0.03–3.00) | 13 | 1.10 (0.03–2.70) | 30 | 2.03 (0.05–3.00) | |||
| Q3 (68–72) | 44 | 1.80 (0.00–3.00) | 19 | 1.22 (0.00–2.67) | 25 | 2.27 (0.00–3.00) | |||
| Q4 (73–84) | 43 | 1.52 (0.00–3.00) | 13 | 1.33 (0.07–2.75) | 30 | 1.61 (0.00–3.00) | |||
| Gender | |||||||||
| Female | 84 | 1.80 (0.00–3.00) | 0.768 | 34 | 1.53 (0.03–2.75) | 0.324 | 50 | 2.00 (0.00–3.00) | 0.887 |
| Male | 85 | 1.60 (0.00–3.00) | 29 | 1.30 (0.00–2.85) | 56 | 2.00 (0.00–3.00) | |||
| Tumor origin | |||||||||
| Duodenum | 14 | 1.30 (0.00–2.85) | 0.052 | 14 | 1.30 (0.00–2.85) | 0.655 | – | 0.988 | |
| Papilla-ampulla I-type | 49 | 1.43 (0.07–2.70) | 49 | 1.43 (0.07–2.70) | – | ||||
| Papilla-ampulla PB-type | 18 | 2.00 (0.60–3.00) | – | 18 | 2.00 (0.60–3.00) | ||||
| Distal bile duct | 45 | 2.00 (0.00–3.00) | – | 45 | 2.00 (0.00–3.00) | ||||
| Pancreas | 43 | 2.07 (0.00–3.00) | – | 43 | 2.07 (0.00–3.00) | ||||
| Tumor origin dichotomized | |||||||||
| Intestinal | 63 | 1.38 (0.00–2.85) | 0.002 | – | – | ||||
| Pancreatobiliary | 106 | 2.00 (0.00–3.00) | – | – | |||||
| T–stage* | |||||||||
| T1 | 6 | 1.70 (0.92–2.55) | 0.280 | 4 | 2.04 (1.47–2.55) | 0.055 | 2 | 1.23 (0.92–1.53) | 0.786 |
| T2 | 21 | 1.90 (0.00–2.93) | 11 | 1.63 (0.13–2.70) | 10 | 2.25 (0.00–2.93) | |||
| T3 | 103 | 1.83 (0.00–3.00) | 25 | 1.43 (0.07–2.85) | 78 | 2.00 (0.00–3.00) | |||
| T4 | 39 | 1.37 (0.00–3.00) | 23 | 1.00 (0.00–2.55) | 16 | 2.00 (0.60–3.00) | |||
| Lymph node metastasis* | |||||||||
| 0 | 63 | 1.33 (0.00–3.00) | 0.086 | 33 | 1.60 (0.03–2.67) | 0.160 | 30 | 1.13 (0.00–3.00) | 0.015 |
| 1–3 | 63 | 1.80 (0.00–3.00) | 19 | 1.40 (0.00–2.85) | 44 | 1.91 (0.00–3.00) | |||
| 4 or more | 43 | 2.00 (0.05–3.00) | 11 | 0.37 (0.10–2.05) | 32 | 2.28 (0.05–3.00) | |||
| Tumor grade | |||||||||
| Well | 11 | 1.47 (0.07–3.00) | 0.249 | 5 | 1.47 (0.07–2.22) | 0.618 | 6 | 1.51 (0.92–3.00) | 0.377 |
| Moderate | 58 | 1.57 (0.00–3.00) | 26 | 1.22 (0.10–2.48) | 32 | 1.95 (0.00–3.00) | |||
| Poor | 96 | 1.92 (0.00–3.00) | 32 | 1.47 (0.00–2.85) | 64 | 2.12 (0.00–3.00) | |||
| Tumor size | |||||||||
| < = 20 mm | 37 | 1.53 (0.07–2.90) | 0.349 | 23 | 1.67 (0.07–2.70) | 0.030 | 14 | 1.06 (0.10–2.90) | 0.031 |
| > 20 mm | 132 | 1.80 (0.00–3.00) | 40 | 1.12 (0.00–2.85) | 92 | 2.03 (0.00–3.00) | |||
| Resection margins | |||||||||
| R0 | 23 | 1.88 (0.13–3.00) | 0.063 | 17 | 1.87 (0.13–2.75) | 0.171 | 6 | 2.28 (0.92–3.00) | 0.638 |
| R1 | 92 | 1.92 (0.00–3.00) | 14 | 1.65 (0.00–2.85) | 78 | 2.03 (0.00–3.00) | |||
| RX | 54 | 1.36 (0.03–3.00) | 32 | 1.08 (0.03–2.70) | 22 | 1.85 (0.10–3.00) | |||
| Perineural growth | |||||||||
| No | 66 | 1.48 (0.00–3.00) | 0.023 | 44 | 1.48 (0.03–2.75) | 0.252 | 22 | 1.52 (0.00–3.00) | 0.065 |
| Yes | 103 | 1.90 (0.00–3.00) | 19 | 1.10 (0.00–2.85) | 84 | 2.00 (0.05–3.00) | |||
| Lymphatic invasion | |||||||||
| No | 61 | 1.63 (0.00–3.00) | 0.526 | 29 | 1.47 (0.00–2.75) | 0.634 | 32 | 1.81 (0.00–3.00) | 0.738 |
| Yes | 108 | 1.80 (0.00–3.00) | 34 | 1.34 (0.07–2.85) | 74 | 2.00 (0.00–3.00) | |||
| Vascular invasion | |||||||||
| No | 128 | 1.62 (0.00–3.00) | 0.274 | 58 | 1.39 (0.00–2.85) | 0.648 | 70 | 1.97 (0.00–3.00) | 0.718 |
| Yes | 41 | 2.00 (0.00–3.00) | 5 | 1.00 (0.10–2.55) | 36 | 2.26 (0.00–3.00) | |||
| Growth in peripancreatic fat | |||||||||
| No | 63 | 1.40 (0.00–3.00) | 0.006 | 41 | 1.43 (0.00–2.70) | 0.751 | 22 | 1.27 (0.00–3.00) | 0.027 |
| Yes | 106 | 1.92 (0.00–3.00) | 22 | 1.23 (0.10–2.85) | 84 | 2.08 (0.00–3.00) | |||
*Pathological staging of T and N.